Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone.
Cytosolic phospholipase A(2)alpha (cPLA(2)alpha), one of the three subtypes of cPLA(2) (alpha, beta and gamma), is thought to be a rate-limiting enzyme in eicosanoid biosynthesis. We developed a novel and potent cPLA(2)alpha inhibitor with an optically active pyrrolidine, termed pyrrophenone, and characterized this compound in detail using enzyme and cellular assay systems. Pyrrophenone, which shows strong inhibition of cPLA(2)alpha activity, is one of the most potent cPLA(2)alpha inhibitors reported to date. Similar inhibitory potencies for cPLA(2)alpha were obtained from three different assays. The inhibitory activity of pyrrophenone is two or three orders of magnitude more potent than arachidonyl trifluoromethyl ketone (AACOCF(3)) under the same assay conditions. Pyrrophenone shows reversible inhibition of cPLA(2)alpha and displays no characteristics of the slow-binding inhibition observed for AACOCF(3). Pyrrophenone also inhibited the esterase and lysophospholipase activities of cPLA(2)alpha. However, the inhibition by pyrrophenone of 14 kDa secretory PLA(2)s, types IB and IIA, was over two orders of magnitude less potent than that for cPLA(2)alpha. Pyrrophenone strongly inhibited arachidonic acid release in calcium ionophore (A23187)-stimulated human monocytic cells (THP-1 cells) in a dose-dependent manner with an IC(50) value of 0.024 microM, followed by suppression of eicosanoid synthesis, and also showed dose-dependent inhibition for interleukin-1-induced prostaglandin E(2) synthesis in human renal mesangial cells with an IC(50) value of 0.0081 microM. The mechanism of inhibition of eicosanoid synthesis in these cell-based assays was due to inhibition of only one step of arachidonic acid release without any effect on cyclo-oxygenase or lipoxygenase pathways. These results suggest that pyrrophenone could be a potential therapeutic agent for inflammatory diseases.
Ono
Takashi
T
Shionogi Research Laboratories, Shionogi and Co. Ltd, Sagisu 5-12-4, Fukushima-ku, Osaka 553-0002, Japan. takashi.ono@shionogi.co.jp
Yamada
Katsutoshi
K
Chikazawa
Yukiko
Y
Ueno
Masahiko
M
Nakamoto
Shozo
S
Okuno
Takayuki
T
Seno
Kaoru
K
D016718:Arachidonic Acid / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002460:Cell Line; D018360:Crystallography, X-Ray; D003600:Cytosol / Q000201:enzymology; D015232:Dinoprostone / Q000096:biosynthesis; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005920:Glomerular Mesangium / Q000187:drug effects / Q000378:metabolism; D054513:Group IV Phospholipases A2; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D008066:Lipolysis; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D011759:Pyrrolidines / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D007375:Interleukin-1; D007476:Ionophores; D011759:Pyrrolidines; C455981:pyrrophenone; D016718:Arachidonic Acid; D000001:Calcimycin; D010741:Phospholipases A; D054513:Group IV Phospholipases A2; D015232:Dinoprostone